Want to see DARE full AI Analyst Report?
DARE Stock Chart & Stats
$1.28
$0.04(3.13%)
At close: 4:00 PM EDT
$1.28
$0.04(3.13%)
Day’s Range― - ―
52-Week Range$1.13 - $3.78
Previous Close$1.33
Volume168.05K
Average Volume (3M)170.74K
Market Cap
$21.57M
Enterprise Value$15.10
Total Cash (Recent Filing)$12.62M
Total Debt (Recent Filing)$1.02M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 05, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding14,979,502
10 Day Avg. Volume281,723
30 Day Avg. Volume170,743
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)75.90
Price to Sales (P/S)209.43
P/FCF Ratio-21.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside681.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$2.10M
Bulls Say, Bears Say
Bulls Say
Significant Non-dilutive Grant FundingMaterial grant awards materially reduce near-term cash burn and fund R&D without immediate equity dilution. This non-dilutive funding supports program advancement and regulatory work over the next 2–6 months and increases optionality for clinical progress before needing large equity raises.
Near-term Commercialization CatalystsImminent first product revenues mark a structural shift toward commercial operations and recurring sales potential. Successful launches and national dispensing could materially improve cash generation and reduce dependency on financing if uptake and reimbursement scale sustainably.
Pipeline Breadth And Regulatory ProgressMultiple program advances and regulatory clearances diversify binary clinical risk. Continued DSMB positives and an IND clearance increase probability of value-driving readouts and expand addressable indications, strengthening long-term commercial optionality across women's health.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flow implies persistent external funding needs. Over a multi-month horizon this elevates dilution and execution risk, constraining investment flexibility and increasing the urgency for successful commercialization or fresh capital to sustain clinical and go-to-market activities.
Thin Equity And Volatile Balance-sheet StabilityVery low equity and historical volatility in capitalization limit strategic flexibility and heighten refinancing risk. A fragile balance sheet reduces the company's buffer against setbacks, may impair counterparties' confidence, and increases the likelihood of dilutive raises under adverse conditions.
Nasdaq Listing Non-compliance And Delisting RiskPotential delisting is a structural corporate governance and financing risk: loss of Nasdaq listing would reduce liquidity, shrink institutional access, and raise the cost of capital. Over several months this can materially constrain fundraising options and strategic partnerships.
Daré Bioscience News
DARE FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was $1.13 and its highest was $3.78 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Daré Bioscience Inc’s market cap is $21.57M.
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on Aug 13, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.097.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is -0.18.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 14,979,502 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
DARE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call described meaningful operational and clinical progress — a first product launch, an approaching prescription product with early prescription activity, positive Phase III interim data for Ovaprene, and non-dilutive funding supporting R&D. However, these positives are balanced by constrained near-term financials: modest Q2 revenue ($200k), limited cash ($12.6M) with a slight working capital deficit, a sizable deferred grant liability (~$15M), and ongoing net losses. Regulatory nuance around Ovaprene completers and the fact that DARE-VVA1 is not yet dispensing also add execution and timing risk. Overall, the update reflects promising commercial and clinical momentum but with material near-term financial and execution challenges.View all DARE earnings summariesDARE Stock 12 Month Forecast
Average Price Target
$10.00
▲(681.25% Upside)
Technical Analysis
Vyome Holdings
―
Lunai Bioworks
―
Passage Bio
―
Neurosense Therapeutics Ltd.
―
Boundless Bio Inc.
―
Ownership Overview
7.23% Insiders
3.88% Mutual Funds
0.16% Other Institutional Investors
84.20% Public Companies and
Individual Investors